Patients with KRAS mutations exhibited a higher rate of overall distant organ metastasis (70.3%), including metastasis to the liver (44.1%) and lungs (19.8%), whereas patients with BRAF mutations showed a higher rate of lymph node metastasis (82.4%). This evidence concerns the gene KRAS and metastatic malignant neoplasm in the lymph nodes.